The parent company, Roche Holding Limited, holds 61.12% of voting rights, maintaining management independence while continuing a strategic alliance. Roche nominates fewer than half of the directors, and a special committee is established to protect minority shareholders.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4519","jir_company_name":"Chugai Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-03-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4519-20260331-01.pdf","jir_short_summary":"The parent company, Roche Holding Limited, holds 61.12% of voting rights, maintaining management independence while continuing a strategic alliance. Roche nominates fewer than half of the directors, and a special committee is established to protect minority shareholders.","jir_summary":"### Relationship with Parent Company and Controlling Shareholders\nRoche Holding Limited is the parent company of Chugai Pharmaceutical and holds 61.12% of voting rights. A basic agreement was signed in December 2001, and business activities based on a strategic alliance commenced in October 2002. Chugai Pharmaceutical is Roche\u2019s sole pharmaceutical business company in Japan, holding the first right of refusal for development and sales of Roche\u2019s development candidates domestically in Japan, while Roche retains the first right of refusal for Chugai Pharmaceutical\u2019s overseas expansion. Both companies strengthen their cooperative relationship while maintaining management independence.\n\n### Minority Shareholder Protection and Corporate Governance\nRoche has the right to nominate fewer than half of the director and auditor candidates and does not hold a majority on the board of directors, ensuring management independence. Independent outside directors account for half of the board, and the nomination committee deliberates on candidate qualifications. Furthermore, important transactions with Roche are reviewed by an independent special committee to protect minority shareholder interests. Roche is subject to restrictions on stock disposals and has preemptive rights when new shares are issued.","jir_financial_highlights":"Voting Rights Ownership Ratio: 61.12% (Unknown)\nRoche Minimum Stock Holding Obligation: 25% or more (Unknown)\nNumber of Directors: 9 (including 3 from Roche and 3 independent outside directors) (Unknown)","jir_category":"","jir_hashtags":"#ChugaiPharmaceutical, #ControllingShareholder, #GeneralIR","jir_key_figures":"Voting Rights Ownership Ratio: 61.12% (Roche Holding Limited)\nRoche Minimum Stock Holding Obligation: 25% or more\nNumber of Directors: 9 (3 from Roche, 3 independent outside directors)","jir_meta_title":"Chugai Pharmaceutical: Roche Holding\u2019s 61.12% Voting Rights and Maintenance of Management Independence","jir_meta_description":"Chugai Pharmaceutical ensures management independence while its parent company, Roche Holding Limited, holds 61.12% of voting rights. Roche nominates fewer than half of the directors and a special committee protects minority shareholders.","jir_og_title":"Chugai Pharmaceutical Explains Strategic Alliance with Roche and Management Independence","jir_og_description":"While the parent company Roche holds 61.12% voting rights, Chugai Pharmaceutical maintains independent management and has established systems to protect minority shareholders.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6836,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-38114","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n